Neurosarcoidosis — Severe Disabling Disease: When Initial Therapy Has Not Achieved Clinical Response

This protocol addresses patients with neurosarcoidosis who have severe, disabling disease and are acutely and severely ill, and in whom the initial treatment line has not produced the expected clinical response within 2–3 months.

Clinical Scenario

The patient has neurosarcoidosis with severe, disabling manifestations and is acutely and severely ill. In this setting, intravenous methylprednisolone for three days or anti-TNF therapy represents the recommended initial approach.

Prior Therapy — Failure Condition

The previous treatment — intravenous methylprednisolone (three days) or anti-TNF therapy (infliximab or adalimumab) — did not achieve the required clinical response within 2–3 months. This protocol is the structured escalation step that follows that failure.

Next-Step Approach (Partial)

Escalation for refractory severe neurosarcoidosis may involve immunosuppressive therapy or procedural interventions addressing CNS involvement. The complete structured regimen is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

For patients who are acutely and severely ill, intravenous methylprednisolone for three days or anti-TNF therapy is recommended.

Mycophenolate and cyclophosphamide have been reported as useful for refractory neurosarcoidosis in selected cases.

View source ↗